A framework for TRIM21-mediated protein depletion in early mouse embryos: recapitulation of Tead4 null phenotype over three days.


Journal

BMC genomics
ISSN: 1471-2164
Titre abrégé: BMC Genomics
Pays: England
ID NLM: 100965258

Informations de publication

Date de publication:
21 Oct 2019
Historique:
received: 11 04 2019
accepted: 13 09 2019
entrez: 23 10 2019
pubmed: 23 10 2019
medline: 27 2 2020
Statut: epublish

Résumé

While DNA and RNA methods are routine to disrupt the expression of specific genes, complete understanding of developmental processes requires also protein methods, because: oocytes and early embryos accumulate proteins and these are not directly affected by DNA and RNA methods. When proteins in the oocyte encounter a specific antibody and the TRIpartite Motiv-containing 21 (TRIM21) ubiquitin-protein ligase, they can be committed to degradation in the proteasome, producing a transient functional knock-out that reveals the role of the protein. However, there are doubts about whether this targeted proteolysis could be successfully used to study mammalian development, because duration of the transient effect is unknown, and also because amounts of reagents delivered must be adequate in relation to the amount of target protein, which is unknown, too. We show that the mouse egg contains up to 1E-02 picomoles/protein, as estimated by mass spectrometry using the intensity-based absolute quantification (iBAQ) algorithm. However, the egg can only accommodate ≈1E-04 picomoles of antibody or TRIM21 without incurring toxic effects. Within this framework, we demonstrate that TRIM21-mediated protein depletion efficiently disrupts the embryonic process of trophectoderm formation, which critically depends on the TEA domain family member 4 (Tead4) gene. TEAD4 depletion starting at the 1-cell stage lasts for 3 days prior to a return of gene and protein expression to baseline. This time period is long enough to result in a phenotype entirely consistent with that of the published null mutation and RNA interference studies: significant underexpression of trophectodermal genes Cdx2 and Gata3 and strongly impaired ability of embryos to cavitate and implant in the uterus. Omics data are available via ProteomeXchange (PXD012613) and GEO (GSE124844). TRIM21-mediated protein depletion can be an effective means to disrupt gene function in mouse development, provided the target gene is chosen carefully and the method is tuned accurately. The knowledge gathered in this study provides the basic know-how (prerequisites, requirements, limitations) to expedite the protein depletion of other genes besides Tead4.

Sections du résumé

BACKGROUND BACKGROUND
While DNA and RNA methods are routine to disrupt the expression of specific genes, complete understanding of developmental processes requires also protein methods, because: oocytes and early embryos accumulate proteins and these are not directly affected by DNA and RNA methods. When proteins in the oocyte encounter a specific antibody and the TRIpartite Motiv-containing 21 (TRIM21) ubiquitin-protein ligase, they can be committed to degradation in the proteasome, producing a transient functional knock-out that reveals the role of the protein. However, there are doubts about whether this targeted proteolysis could be successfully used to study mammalian development, because duration of the transient effect is unknown, and also because amounts of reagents delivered must be adequate in relation to the amount of target protein, which is unknown, too.
RESULTS RESULTS
We show that the mouse egg contains up to 1E-02 picomoles/protein, as estimated by mass spectrometry using the intensity-based absolute quantification (iBAQ) algorithm. However, the egg can only accommodate ≈1E-04 picomoles of antibody or TRIM21 without incurring toxic effects. Within this framework, we demonstrate that TRIM21-mediated protein depletion efficiently disrupts the embryonic process of trophectoderm formation, which critically depends on the TEA domain family member 4 (Tead4) gene. TEAD4 depletion starting at the 1-cell stage lasts for 3 days prior to a return of gene and protein expression to baseline. This time period is long enough to result in a phenotype entirely consistent with that of the published null mutation and RNA interference studies: significant underexpression of trophectodermal genes Cdx2 and Gata3 and strongly impaired ability of embryos to cavitate and implant in the uterus. Omics data are available via ProteomeXchange (PXD012613) and GEO (GSE124844).
CONCLUSIONS CONCLUSIONS
TRIM21-mediated protein depletion can be an effective means to disrupt gene function in mouse development, provided the target gene is chosen carefully and the method is tuned accurately. The knowledge gathered in this study provides the basic know-how (prerequisites, requirements, limitations) to expedite the protein depletion of other genes besides Tead4.

Identifiants

pubmed: 31638890
doi: 10.1186/s12864-019-6106-2
pii: 10.1186/s12864-019-6106-2
pmc: PMC6805607
doi:

Substances chimiques

CDX2 Transcription Factor 0
Cdx2 protein, mouse 0
DNA-Binding Proteins 0
Muscle Proteins 0
Proteome 0
RNA, Messenger 0
TEA Domain Transcription Factors 0
Tead4 protein, mouse 0
Transcription Factors 0
Ubiquitin-Protein Ligases EC 2.3.2.27

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

755

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : DFG BO-2540/4-3
Organisme : Deutsche Forschungsgemeinschaft
ID : DFG FU-583/5-1

Références

J Cell Biol. 1990 Oct;111(4):1491-504
pubmed: 2211822
Nat Cell Biol. 2006 Sep;8(9):1035-7
pubmed: 16906143
Biol Reprod. 2001 Oct;65(4):1260-70
pubmed: 11566752
Dev Biol. 1984 Oct;105(2):488-99
pubmed: 6207062
Development. 2010 Dec;137(24):4159-69
pubmed: 21098565
J Immunol Methods. 2015 Feb;417:86-96
pubmed: 25536073
Nucleic Acids Res. 2013 Jan;41(Database issue):D1063-9
pubmed: 23203882
Development. 2007 Nov;134(21):3827-36
pubmed: 17913785
Nat Rev Mol Cell Biol. 2013 Jan;14(1):55-61
pubmed: 23258296
Clin Exp Reprod Med. 2015 Mar;42(1):1-7
pubmed: 25874167
Nat Immunol. 2013 Feb;14(2):172-8
pubmed: 23222971
Mol Hum Reprod. 2011 May;17(5):296-304
pubmed: 21266449
Science. 2002 Aug 23;297(5585):1343-5
pubmed: 12193786
BMC Bioinformatics. 2015 May 22;16:169
pubmed: 25994840
Reproduction. 2010 May;139(5):809-23
pubmed: 20106898
Methods Mol Biol. 2009;518:135-56
pubmed: 19085140
J Reprod Fertil. 1976 May;47(1):145-7
pubmed: 946819
Cell Cycle. 2011 Jun 1;10(11):1853-60
pubmed: 21543895
Biol Reprod. 1999 Jun;60(6):1410-8
pubmed: 10330100
Stem Cell Rev Rep. 2016 Jun;12(3):276-84
pubmed: 26892267
Cell. 2017 Dec 14;171(7):1692-1706.e18
pubmed: 29153837
Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8263-7
pubmed: 8058792
Int J Dev Biol. 1991 Dec;35(4):389-97
pubmed: 1666294
Proc Natl Acad Sci U S A. 2007 Apr 10;104(15):6200-5
pubmed: 17400754
J Biol Chem. 2009 Oct 16;284(42):28729-37
pubmed: 19700764
Proc Natl Acad Sci U S A. 1973 Dec;70(12):3899-903
pubmed: 4521215
Mol Reprod Dev. 1995 Jun;41(2):232-8
pubmed: 7654376
Int Rev Cell Mol Biol. 2015;316:227-65
pubmed: 25805126
Biol Reprod. 2002 Aug;67(2):546-54
pubmed: 12135894
Development. 1994 Aug;120(8):2347-57
pubmed: 7925035
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Dev Biol. 2010 Aug 1;344(1):66-78
pubmed: 20430022
Clin Exp Reprod Med. 2014 Jun;41(2):47-61
pubmed: 25045628
Dev Cell. 2014 Aug 25;30(4):410-22
pubmed: 25127056
Mol Cell Proteomics. 2014 Dec;13(12):3497-506
pubmed: 25225357
Dev Dyn. 1995 Jul;203(3):253-310
pubmed: 8589427
J Proteome Res. 2016 Aug 5;15(8):2407-21
pubmed: 27225728
Biol Reprod. 2000 Dec;63(6):1610-6
pubmed: 11090427
Sci Rep. 2015 Oct 13;5:15034
pubmed: 26461180
Cell. 1998 Oct 30;95(3):379-91
pubmed: 9814708
J Reprod Fertil. 1981 Mar;61(2):307-15
pubmed: 7205777
J Embryol Exp Morphol. 1964 Mar;12:113-21
pubmed: 14155399
J Cell Sci. 2016 Mar 1;129(5):881-91
pubmed: 26906420
Yonsei Med J. 1973;14:63-90
pubmed: 4804134
Reproduction. 2014 Jul;148(1):55-72
pubmed: 24686459
PLoS One. 2012;7(1):e30344
pubmed: 22295082
J Cell Sci. 1977 Apr;24:167-94
pubmed: 893541
Dev Cell. 2008 Sep;15(3):416-25
pubmed: 18804437
Proc Natl Acad Sci U S A. 2012 May 8;109(19):7362-7
pubmed: 22529382
Cloning Stem Cells. 2006;8(1):24-40
pubmed: 16571075
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
Mol Immunol. 2007 Mar;44(9):2406-14
pubmed: 17118455
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
Mol Biol Cell. 2011 Sep;22(18):3465-77
pubmed: 21795393
Development. 2009 Jul;136(13):2247-54
pubmed: 19502485
Genome Biol. 2019 Jan 23;20(1):19
pubmed: 30674345
J Cell Biol. 1990 Oct;111(4):1519-33
pubmed: 2211824
Development. 1988 Oct;104(2):219-34
pubmed: 2474425
Curr Top Dev Biol. 2013;102:1-34
pubmed: 23287028
Nat Neurosci. 2013 Mar;16(3):365-74
pubmed: 23334578
J Reprod Fertil. 1967 Jun;13(3):413-20
pubmed: 6027845
Cell Rep. 2017 Dec 26;21(13):3957-3969
pubmed: 29281840
Development. 2010 Feb;137(3):395-403
pubmed: 20081188
Sci Rep. 2016 Jul 11;6:29735
pubmed: 27405720
Mol Cell Proteomics. 2012 Mar;11(3):M111.014050
pubmed: 22278370
Am J Pathol. 1974 Oct;77(1):103-118
pubmed: 4447121
Nat Methods. 2009 May;6(5):359-62
pubmed: 19377485
Development. 2018 Oct 1;145(19):
pubmed: 30201685
Nature. 2011 May 19;473(7347):337-42
pubmed: 21593866
Mech Dev. 2008 Mar-Apr;125(3-4):270-83
pubmed: 18083014
Mol Cell Proteomics. 2008 Apr;7(4):672-83
pubmed: 18045802
Reproduction. 2017 Dec;154(6):R161-R170
pubmed: 28916717
Development. 2013 Sep;140(17):3680-90
pubmed: 23903192

Auteurs

Steffen Israel (S)

Max Planck Institute for Molecular Biomedicine, Roentgenstrasse 20, 48149, Muenster, Germany.

Ellen Casser (E)

Max Planck Institute for Molecular Biomedicine, Roentgenstrasse 20, 48149, Muenster, Germany.

Hannes C A Drexler (HCA)

Max Planck Institute for Molecular Biomedicine, Roentgenstrasse 20, 48149, Muenster, Germany.

Georg Fuellen (G)

Rostock University Medical Center, Institute for Biostatistics and Informatics in Medicine and Aging Research (IBIMA), Ernst-Heydemann-Strasse 8, 18057, Rostock, Germany.

Michele Boiani (M)

Max Planck Institute for Molecular Biomedicine, Roentgenstrasse 20, 48149, Muenster, Germany. mboiani@mpi-muenster.mpg.de.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH